申请人:The Angstrom Pharmaceuticals, Inc.
公开号:US20040204348A1
公开(公告)日:2004-10-14
uPAR-targeting cyclic peptide compounds have 11 amino acids that correspond to human uPA(20-30) [SEQ ID NO:2], or are substitution variants at selected positions. The N and C terminal residues of these peptides are joined by a linking group L, so that the linear dimension between the &agr;-carbons of the first and the eleventh amino acids is between about 4 and 12 Angstrom units. These cyclic peptides may be further conjugated to diagnostic labels or therapeutic moieties such as radionuclides. Such compounds are useful for targeting uPAR expressed in pathological tissues and for inhibiting the binding of uPA to the uPAR. The pharmaceutical and therapeutic compositions inhibit cell migration, cell invasion, cell proliferation or angiogenesis, or induce apoptosis, and are thus useful for treating diseases or condition associated with undesired cell migration, invasion, proliferation, or angiogenesis, most notably cancer. The cyclic peptides are also used to detect and isolate cells expressing uPAR.
uPAR-靶向循环肽化合物由11个氨基酸组成,对应于人类uPA(20-30) [SEQ ID NO:2],或者在选定的位置进行替换变异。这些肽的N和C端残基由连接基L连接,使得第一个和第十一个氨基酸的α-碳之间的线性尺寸在约4到12埃之间。这些循环肽可以进一步与诊断标记或治疗成分(如放射性核素)结合。这样的化合物可用于靶向在病理组织中表达的uPAR,并抑制uPA与uPAR的结合。这些制药和治疗组合物抑制细胞迁移、侵袭、增殖或血管生成,或诱导细胞凋亡,因此可用于治疗与不良细胞迁移、侵袭、增殖或血管生成相关的疾病或情况,尤其是癌症。这些循环肽也用于检测和分离表达uPAR的细胞。